This page contains a Flash digital edition of a book.
Osteoporosis


Table 3: Osteoporosis Treatments Generic Name (Brand) Fracture Type Reduced Dose and Frequency Administration


Calcitonin (Miacalcin®)60 Raloxifene (Evista®)61


Alendronate (Fosamax®)62


Vertebral Vertebral Vertebral and hip 200IU spray daily 60mg daily 5–10mg daily, 30–70mg weekly Nasal spray Tablet Tablet


Potential Long-term Side Effects


None


Blood clots and risk for dying from stroke ONJ, chest pain,


heartburn, swallowing problems, esophagus


problems, and atypical fractures


Ibandronate (Boniva®)63 Vertebral 2.5mg daily; 150mg monthly; 3mg infusion quarterly


Tablet or intravenous infusion


Swallowing problems, chest pain, heartburn, stomach/esophageal


ulcers, low calcium, pain in extremities, and atypical fractures


Risedronate (Actonel®)64


Non-vertebral, including hip


5mg daily;


30–35mg weekly; 150mg monthly


Tablet


Swallowing problems, chest pain, heartburn, stomach/esophageal


Back and joint pain, stomach, pain, flu-like symptoms, eye


ulcers, low calcium, pain inflammation, allergic, in extremities, ONJ, and and severe skin reactions atypical fractures


Zoledronic acid (Reclast®)65


Teriparatide (Forteo®)66


Vertebral, hip, and Non-vertebral


Vertebral and non-vertebral


Denosumab (Prolia®)67


Vertebral, hip, non-vertebral


ONJ = osteonecrosis of jaw.


rate of 79.1% for any fracture (for a threshold of 20%) and 79.5% for hip fracture (with a threshold of 3%).16


The nomograms were more effective


in their assessment of fracture risk owing to their higher accuracy in predicting fracture, especially hip fractures. This study used BMD results in its analysis.


In 2002, before the development of FRAX, COSC established risk factor-based guidelines to aid clinical judgment in combination with BMD. The COSC guidelines are similar to those of NOF: treat any patient with a T score below -2.5 and evaluate for treatment those with T scores below -1.5. COSC classifies risk factors as either major or minor (see Table 2). Treatment is recommended for patients with one major risk or two minor risk factors present. In addition, COSC recommends treatment for patients using prednisone 7.5mg daily, regardless of their T-score. This is the only guideline that incorporates a dose relationship. The use of the COSC risk factors is the simplest assessment method, but is dependent on BMD.


Treatment Options in Osteoporosis Once it has been decided that a patient is at risk for fracture based on their BMD and other risk factors, they should receive individualized


22


The physician can then individualize pharmacological treatment based on efficacy and patient preferences. Multiple treatment options can be individualized based on the preferences of the physician and patient to maximize effectiveness and adherence.


Table 3 summarizes some of the major treatment options, including the type of fracture reduced by the medication, administration type, and frequency of administration. All medications are effective in reducing vertebral fractures but vary in their ability to reduce hip and non-vertebral fractures. Medications can be delivered orally daily, weekly or monthly, by intravenous infusion every three months or 12 months, or by subcutaneous injection daily or twice yearly.


Physicians should first begin with therapeutic agents that have robust fracture reduction across multiple sites, such as vertebrae, non-vertebrae, and hip. These therapies include alendronate, risedronate, ibandronate, zoledronate, denosumab, and teriparatide. For second-choice therapies, physicians can use selective estrogen


US MUSCULOSKELETAL REVIEW


treatment. Treatment advice from the physician should begin with lifestyle modifications, including regular exercise, smoking and alcohol cessation, and diet supplementation with calcium (12,000mg/day) and vitamin D (800–1,000IU/day).2


5mg infusion annually


20µg subcutaneous injection daily


60mg injection biannually


Intravenous infusion over 15 minutes


Kidney problems, ONJ, atrial fibrillation, and atypical fractures


Subcutaneous injection Increased calcium in blood


Subcutaneous injection ONJ, atypical fractures


Low blood calcium, bone, and joint pain


Decrease in blood pressure


when changing positions, nausea, joint pain, and osteosarcoma


Skin problems and serious


infections and hypocalcemia


Diarrhea, mild flu-like symptoms, and stomach pain


Short-term Side Effects


Nose bleed, runny nose, back and joint pain


Hot flashes, leg cramps, and feet swelling Flu-like symptoms, allergic reactions, and stomach pain


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68